ArticleCellular signalling2024
Octreotide protects against LPS-induced endothelial cell and lung injury.
Article in Cellular signalling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Ceapin-A7 counteracts the protective effects of Lanreotide in endothelial cells.Aspects of molecular medicine · 2026Article
- Octreotide Counteracts IFN-γ-Induced Endothelial Inflammation.Journal of biochemical and molecular toxicology · 2026Article
- Lanreotide in endothelial corneal inflammation.Hormones (Athens, Greece) · 2026Article
- Inhibition of junctional protein disruption by 2,4,6-trihydroxy-3-geranyl acetophenone in lipopolysaccharide-induced endothelial hyperpermeability via GEF-H1/RhoA/ROCK pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Protective Effects of Pasireotide in LPS-Induced Acute Lung Injury.Pharmaceuticals (Basel, Switzerland) · 2025Article
- NEK kinases in cell cycle regulation, DNA damage response, and cancer progression.Tissue & cell · 2025Review
- Pasireotide Exerts Anti-Inflammatory Effects in the Endothelium.Journal of biochemical and molecular toxicology · 2025Article
- Article
- ATF6 inhibition suppresses the protective effects of pasireotide in human and bovine endothelial cells.Vascular biology (Bristol, England) · 2025Article
- Unfolded protein response modulates the effects of GHRH antagonists in experimental models ofTissue barriers · 2025Article
- Lanreotide protects against LPS-induced inflammation in endothelial cells and mouse lungs.Tissue barriers · 2025Article
- NEK2 inhibition alleviates lipopolysaccharide-induced endothelial injury.ASPET discovery · 2025Article
- Synthetic somatostatin analogs beyond cancer.Pituitary · 2024Article
- Involvement of ATF6 in Octreotide-Induced Endothelial Barrier Enhancement.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Growth hormone in disease and treatment (Review).Medicine internationalReview
- Growth hormone suppression in endothelial dysfunction.Cell cycle (Georgetown, Tex.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Growth hormone (GH) is a crucial regulator of growth, cell reproduction, and regeneration; and it is controlled by growth hormone-releasing hormone (GHRH) and somatostatin. Lipopolysaccharides (LPS) can compromise endothelial function, leading to increased inflammation and vascular leak. Octreotide (OCT) is an FDA-approved synthetic somatostatin analog (SSA) used to treat acromegaly and neuroendocrine tumors. The present study investigates the effects of OCT on LPS-induced injury in bovine and human lung endothelial cells, as well as in mouse lungs. Our in vitro observations suggest that OCT effectively counteracts LPS-induced endothelial leak, inflammation, and reactive oxygen species (ROS) generation. Furthermore, OCT reduces bronchoalveolar lavage fluid (BALF) protein concentration in an experimental model of Acute Lung Injury (ALI). Our study suggests that OCT mitigates LPS-induced endothelial cell and lung injury, suggesting that it may represent an exciting therapeutic possibility in diseases related to barrier dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.